#

Wolfgang Seibold

Chief Investment Officer & Partner

Experienced VC and PE investor across all stages with dedication to transformative technologies; passionate networker, initiative taker and growth manager; trusted advisor to multiple start-ups, large corporations and industry associations.

Wolfgang Seibold

As Partner and CFO of Hitachi Ventures, Wolfgang has been a driving force since the formation of Hitachi Ventures, and has led many of its investments in Digital, DeepTech and Healthcare.

Wolfgang has managed and run successful international VC and Private Equity funds for over two decades. Prior to Hitachi Ventures he was Managing Partner for AGIC Capital, a billion-dollar PE fund investing in Industrial, Medical and Digital Technologies. And before that he was a partner at Earlybird, investing in Fintech, B2B SaaS, Semiconductor and Environmental Technologies.

For many years Wolfgang served on boards of industry associations such as the German Venture Capital and Private Equity Association (BVKAP), Munich Network, CTI Invest and others.

Wolfgang studied Physics and Mathematics in Ulm, Germany and Newcastle upon Tyne, UK, and has an MBA from INSEAD in France. He started his professional career as a consultant at BCG.

Areas of Interest
  • AI
  • Autonomous Mobility
  • Computer Vision
  • Digital Technologies
  • Drug Discovery
  • Fintech
  • Genetics
  • Manufacturing Technologies
  • Nuclear Fusion
  • Quantum Technologies
  • Regenerative Medicine
  • Robotics
  • Semiconductors

Perspectives

View All
#
#
Hitachi Ventures raises $400M fund to invest in everything from fusion to AI
February 5, 2025
Firm News

Hitachi Ventures raises $400M fund to invest in everything from fusion to AI

link
Hitachi ups startup investment to $1bn as AI wave grows
February 5, 2025
Firm News

Hitachi ups startup investment to $1bn as AI wave grows 

link
January 14, 2025
Portfolio News

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

link
StrikeReady Raises $12 Million for Industry-First AI Security Command Platform Purpose-Built for Modern SOC Teams
April 9, 2024
Portfolio News

StrikeReady Raises $12 Million for Industry-First AI Security Command Platform Purpose-Built for Modern SOC Teams

link
Thea Energy Featured
February 8, 2024
Why We Invested

Thea Energy raises $20M Series A for pixel-inspired fusion power plants

link
Scipher Featured
September 8, 2023
Portfolio News

Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients

link
Scipher Medicine Closes $110M Financing
February 24, 2022
Portfolio News

Scipher Medicine Closes $110 Million Financing

link
The Galien Foundation Honors Excellence in Scientific Innovation at 2021 Prix Galien Awards Gala
October 29, 2021
Portfolio News

The Galien Foundation Honors Excellence in Scientific Innovation at 2021 Prix Galien Awards Gala

link
SOPHiA Genetics Featured Image
July 28, 2021
Portfolio News

IPO of our portfolio company Sophia Genetics on July 24th, 2021

link
Huma Featured Image
June 1, 2021
Portfolio News

Hitachi Ventures investing in Huma

link
SOPHiA Genetics and Hitachi
March 25, 2021
Portfolio News

Sophia Genetics announces collaboration with Hitachi Ltd.

link
Rescale Series C
February 2, 2021
Portfolio News

Hitachi Ventures investing in Rescale

link
Taranis Featured Image
July 21, 2020
Portfolio News

Hitachi Ventures investing in Taranis

link
Arsenal Bio Logo

ArsenalBio develops programmable CAR-T therapies using genetic circuits, CRISPR, AI, and data analytics for cancer treatment

ArsenalBio develops programmable cell therapies using genetic circuits to enhance CAR-T therapies for solid tumors. By controlling specificity, on-tumor activation, potency, and durability, the company leverages CRISPR, AI, and data analytics to reprogram T cells and identify new drug candidates for improved cancer treatment.

CEO

Ken Drazan

Sectors

Healthcare

Stage

Series C

HQ

California

Deal Team

Wolfgang Seibold
Joanna Soroka

Bioptimus Logo

Bioptimus is building a universal multi-scale, multi-modal Foundation Model for Biology to revolutionize biomedicine research.

Bioptimus is building the world’s first universal multi-scale, multi-modal Foundation Model for Biology. By leveraging expertise from Google DeepMind and the unique MOSAIC dataset, Bioptimus aims to uncover intricate relationships across biological systems at unprecedented scales. This groundbreaking approach is poised to drive the next frontier in biomedicine research.

CEO

Jean-Philippe Vert

Sectors

Digital

Healthcare

Stage

Series A

HQ

Paris

Deal Team

Wolfgang Seibold
Joanna Soroka
Marina Du
Aditi Purandare

Cure51 Logo

Cure51 is building the first global database of cancer survivors to uncover new life-saving medicines.

Cure51 is creating the world’s first global, diversified clinical and molecular database of cancer survivors to uncover life-saving medicines. Through a collaborative network, multiomics, and special biology, it aims to identify therapeutic targets for cancer treatment. The company, co-created with oncology centers, focuses on three cancer indications.

CEO

Nicolas Wolikow

Sectors

Healthcare

Stage

Seed

HQ

Paris

Deal Team

Wolfgang Seibold
Joanna Soroka
Marina Du

Grow Inc. Logo

GROW Inc’s technology and services solutions enable super funds and fund managers to optimise operations and step into the future of financial services.

Grow Inc provides wealth administration platform technology and services to the wealth management industry in Australia. Grow’s wealth administration platform helps superannuation funds maintain member records, process fund allocation changes, create workflows and perform calculations based on business rules. Grow also provides administration services including the mailing out and receiving of physical forms, contact centre management and member communication.

CEO

Mathew Keeley

Sectors

Digital

Stage

Series D

HQ

Syndey

Deal Team

Wolfgang Seibold
Galina Sagan
Elena Ballesteros

Huma Logo

Digital health platform using real-time health data to improve clinical care and research

Digital health platform enabling ‘Hospital at Home’ remotely collect patient-generated data, greater access to care outside of a conventional setting, improving efficiency and empowering patients to better manage their own health Companion App (SaMD) secure, scalable and fully compliant platform accelerates time to market for pharma and medtech customers’ regulated digital health products
Digital Clinical Trial (DCT) easy-to-build and digital-first clinical trial platform that deploys trial at speed, achieve higher accuracy with continuous data collection and near real-time reporting.

CEO

Dan Vahdat

Sectors

Digital

Healthcare

Stage

Series D

HQ

London

Deal Team

Wolfgang Seibold

Development of thermal interface materials based on nanostructured copper to enhance heat transfer from high-performance chips.

NovoLINC develops next-generation thermal interface materials based on nanostructured copper to dramatically enhance heat transfer from high-performance chips. As AI workloads push chip power densities higher, making thermal management a key bottleneck in data-center design – NovoLINC’s technology delivers significantly lower thermal resistance and let’s chips run cooler and more reliably.

CEO

Ning Li

Sectors

Digital

Stage

Stage +

HQ

Pittsburgh

Deal Team

Wolfgang Seibold
Vamsi Patti
Pratik Malhotra

Regrello Logo

The AI operating system for manufacturing and supply chain operations.

Exited October 2025

Regrello is building an AI-powered supply chain manager that combines traditional and generative AI to automate end-to-end operational and back-office workflows. Regrello auto generates process diagrams and eliminates manual work, accelerates cycle times, and transforms fragmented processes into intelligent, adaptable systems built for speed, scale, and efficiency.

CEO

Aman Naimat

Sectors

Digital

Industrial

Stage

Series A

HQ

California

Deal Team

Wolfgang Seibold
Jan Marchewski
Pratik Malhotra

Relation Therapeutics combines AI, genomic medicine, and Lab-in-the-Loop to build disease maps and discover novel drug targets.

Relation Therapeutics is a drug discovery company focused on genomics, combining advanced ActiveGraph AI models with Lab-in-the-Loop. This integration allows for seamless single-cell analysis at scale, creating rich maps of disease biology to identify novel drug targets. Their approach accelerates drug discovery by linking genomics and AI-driven insights.

CEO

David Roblin

Sectors

Digital

Healthcare

Stage

Seed

HQ

London

Deal Team

Wolfgang Seibold
Joanna Soroka
Marina Du

Fully automated and ultra-scalable hybrid cloud platform enabling big compute for breakthroughs in science and engineering.

Developer of cloud-based infrastructure platform designed to facilitate scientific and engineering simulations. The company’s platform provides an infinite scale, customization tools, and the ability to make adjustments optimized for specific workloads in order to decrease turnaround times, enabling businesses to transform information technology into unified, agile environments while improving the total outcome.

CEO

Joris Poort

Sectors

Digital

Stage

Series C

HQ

California

Deal Team

Wolfgang Seibold
Galina Sagan

Scipher Medicine

Scipher Medicine uses transcriptomics and network biology to uncover molecular signatures for autoimmune disease diagnostics and drug discovery.

Scipher Medicine leverages transcriptomics and real-world evidence to build a precision immunology platform for complex diseases. Combining interactome and network biology with proprietary patient transcriptomics data, the platform uncovers unique molecular disease signatures in autoimmune disease patients, advancing diagnostics, drug discovery, and personalized treatment development.

CEO

Reginald Seeto

Sectors

Healthcare

Stage

Series D

HQ

Massachusetts

Deal Team

Wolfgang Seibold
Joanna Soroka

Data analytics solution to support healthcare professionals by maximizing power of data-driven precision medicine.

Exited

Sophia Genetics offers a decentralized, AI-driven data analytics platform integrating genomics, radiology, and clinical data. Covering cancer, cardiology, nephropathies, and hereditary diseases, the platform connects over 750 global health institutions. It seamlessly integrates into existing workflows, ensuring data ownership while powering precision medicine and actionable insights for healthcare providers and biopharma.

CEO

Jurgi Camblong

Sectors

Healthcare

Stage

Exited

HQ

Massachusetts

Deal Team

Wolfgang Seibold

Revolutionizing Cyber Security with an AI-powered Command Center.

StrikeReady’s functionality scope goes far beyond SoC automation co-pilots, while combining elements of SIEM (proactive), SOAR (reactive/defensive) and workflow automation solutions with AI-led agent-based assistance.
StrikeReady augments security professionals’ work by providing a common workspace that empowers faster, better decision-making.

CEO

Yasir Khalid

Sectors

Digital

Stage

Series A

HQ

Texas

Deal Team

Wolfgang Seibold
Galina Sagan
Tobias Graf

Agriculture intelligence company offering high precision aerial surveillance imagery to prevent crop yield loss.

Developer of an AI-powered crop analytics platform designed to unlock demand intelligence for agribusiness. The company’s platform uses computer vision, data science, and deep learning algorithms to make informed decisions by detecting early symptoms of weeds, uneven emergence, nutrient deficiencies, disease or insect infestations, water damage, and machinery problems, enabling farmers to acquire accurate insights to address issues while increasing yields.

CEO

Opher Flohr

Sectors

Digital

Environment

Stage

Series D

HQ

California

Deal Team

Wolfgang Seibold
Galina Sagan

Developer of a fusion energy system intended to create a limitless source of zero-emission power for a sustainable future with an improved stellarator approach.

Thea is a planar coil stellarator design revolutionizing fusion through arrays of planar magnets that enable new ways of designing, manufacturing, and dynamically controlling stellarators to achieve commercial fusion in a cost-competitive way.

CEO

Brian Berzin

Sectors

Environment

Stage

Series A

HQ

Texas

Deal Team

Wolfgang Seibold
Tobias Jahn
Elena Ballesteros
Tobias Graf

# # # # # # # # # # #